Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

51 results about "Orexin" patented technology

Orexin (/ɒˈrɛksɪn/), also known as hypocretin, is a neuropeptide that regulates arousal, wakefulness, and appetite. The most common form of narcolepsy, in which the sufferer experiences brief losses of muscle tone (cataplexy), is caused by a lack of orexin in the brain due to destruction of the cells that produce it.

Method of treating depression using seltorexant

PCT designated stage expiredWO2025003991A1Organic active ingredientsNervous disorderHepatic impairmentReduced dose
A method of treating an orexin-2 mediated disorder in a human subject in need thereof is provided. The method comprises administering seltorexant or a pharmaceutically acceptable salt or hydrate thereof at a therapeutically effective daily dose to the subject, when the subject does not have a hepatic impairment. The method also comprises administering seltorexant or the pharmaceutically acceptable salt or hydrate thereof at a reduced dose less than the daily dose to the subject, when the subject has moderate hepatic impairment.
Owner:JANSSEN PHARMA NV

Novel serum protein marker combination for evaluating depth of anesthesia and application of novel serum protein marker combination

PendingCN121899423ADisease diagnosisBiological testingNeurophysiological MonitoringReceptor subunit
The invention belongs to the technical field of in-vitro diagnosis and anesthesia monitoring. The invention discloses a serum protein marker combination for evaluating anesthesia depth and application of the serum protein marker combination. The composition is composed of orexin, S100 calcium binding protein B, C reactive protein and gamma-aminobutyric acid A type receptor alpha1 subunit, and can synergistically reflect the anesthesia sedation state from multiple dimensions. The invention also provides a detection kit containing the marker and application of the detection kit in evaluation of anesthesia depth. The combination has the advantages of being high in accuracy, objective, stable and easy to detect, can serve as an effective supplementary tool of an existing nerve electrophysiology monitoring technology, and provides a new reference means for intraoperative sedation depth monitoring and precise anesthesia management.
Owner:JIANGSU TAIZHOU PEOPLES HOSPITAL

Method and compound for preparing orexin-2 receptor antagonist, and low-impurity lybologxant

The invention relates to a method and a compound for preparing an orexin-2 receptor antagonist, and lebovolisan with less impurities, and particularly relates to a method and a compound for preparing an orexin-2 receptor antagonist. A process for preparing a compound of Formula (XI) and a compound are disclosed. Further, the present application discloses a compound of formula (XI) comprising a small amount of impurities. # imgabs0 #
Owner:EISAI R&D MANAGEMENT CO LTD

Oxazepin Derivative

Novel compounds are provided with excellent orexin type 2 receptor agonist activity. The compounds are represented by Formula (I) or pharmaceutically acceptable salts thereof.
Owner:TEIJIN PHARMA CO LTD

Administration of orexin type 2 receptor agonists

The present invention discloses the use of an orexin type 2 receptor (OX2R) agonist at a non-wake-up concentration. Also disclosed are compositions and methods for administering an OX2R agonist to a subject (e.g., a mammal) in need thereof in a dose that provides a plasma concentration of the OX2R agonist that is equal to or lower than a maximum non-waking plasma concentration of the OX2R agonist. Also disclosed are compositions and methods for treating narcolepsy type 1 (NT1) in a subject in need thereof by maintaining the plasma concentration of the OX2R agonist at or below the maximum non-wake-up concentration of the OX2R agonist after administration.
Owner:TAKEDA PHARMA CO LTD

Method for quantifying active orexin A

A method for quantifying active orexin A in a sample, the method comprising: a step in which the sample is brought into contact with a monoclonal antibody that recognizes the C-terminal side of orexin A to isolate orexin class A; a step for digesting the separated orexin class A with a protease to obtain a peptide comprising the amino acid sequence represented by SEQ ID NO: 1; and a step for performing mass spectrometry on the peptide.
Owner:EISAI R&D MANAGEMENT CO LTD

Method for diagnosing diseases and disorders associated with altered orexin-a levels

PCT designated stageWO2026132444A1Biological testingDiseaseBiologic marker
The present invention relates to in vitro methods for diagnosing or prognosing diseases and disorders associated with altered orexin-A levels. It further relates to in vitro methods for monitoring the effect of a treatment or the evolution of a disease or disorder associated with altered orexin-A levels. It also relates to the use of orexin-A fragment as biomarker for the in vitro diagnosis of diseases and disorders associated with altered orexin-A levels.
Owner:CENTRE HOSPITALIER UNIVERSITAIRE DE MONTPELLIER +1

Macrocyclic Orexin Agonists

UndeterminedAE202602093AArylPharmaceutical drug
The present invention relates to aryl thiol macrocycles of Formula (I) wherein R1, R2, RA1, X1, X2, X3, X4, L, X5, and Ring A are as described in the description, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more compounds of Formula (I), and their use as agonists of the orexin-2 receptor.
Owner:IDORSIA PHARMACEUTICALS LTD

Pyrrolo[1, 2-c]imidazole derivatives as orexin type 2 receptor agonists and methods of use thereof

The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity.A compound represented by the formula (I):wherein each symbol is as described in the specification, or a salt thereof, is useful as an agent for the prophylaxis or treatment of narcolepsy.
Owner:TAKEDA PHARMA CO LTD

Sleep-improving agent

This sleep-improving agent contains one peptide among the following (I)-(IV). (I) is a peptide having an amino acid sequence of a prepro-orexin C-terminal peptide. (II) is a peptide that shares an amino acid sequence identity of at least 90% with the amino acid sequence of the (I) prepro-orexin C-terminal peptide. (III) is a peptide that is a part of the amino acid sequence of the (I) prepro-orexin C-terminal peptide. (IV) is a mutant form of the (I) or (III) peptide in which one or two amino acids are deleted, substituted, added, or inserted in the (I) or (III) peptide.
Owner:UNIVERSITY OF TOYAMA

Pyrazole and imidazole derivatives as dual orexin and kappa-opioid receptors modulators composition, methods for treating neurological and psychiatric disorders

The present disclosure is directed to substituted Pyrazole and Imidazole derivatives of compounds that are antagonists and / or modulators of orexin and kappa-opioid receptors, and which are useful in the treatment or prevention of neurological, psychiatric, cardiovascular and cancer disorders and diseases in which orexin and kappa-opioid receptors are involved or implicated. The disclosure is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which orexin and kappa-opioid receptors are involved.
Owner:HAGER BIOSCIENCES LLC

Antibodies for detecting orexin and related products and uses thereof

PendingCN122356285AHeavy chainBiomedicine
This invention discloses an antibody for detecting orexin, related products, and applications, belonging to the field of biomedical detection technology. In the heavy chain variable region of the antibody, HCDR1, HCDR2, and HCDR3 are the amino acid sequences of HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:7; in the light chain variable region of the antibody, LCDR1, LCDR2, and LCDR3 are the amino acid sequences of LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:8. The antibody of this invention exhibits high binding activity to orexin, effectively improving the specificity and sensitivity of orexin detection while significantly reducing detection costs.
Owner:SHAOXING WOMEN & CHILDRENS HOSPITAL

Crystal of oxazepine derivative or crystal of solvate thereof

[Problems] An object of the present invention is to provide a crystal of an oxazepine derivative or a crystal of a solvate thereof, which has excellent orexin type 2 receptor agonist activity and is useful for the prevention or treatment of, for example, narcolepsy, idiopathic hypersomnia, hypersomnia. [Solution] A crystal of a compound represented by the following formula (I): [in the formula (I), R1 represents a methyl group or a methyl group substituted with 1 to 3 fluorine atoms; and R2 and R3 each independently represent a hydrogen atom or a fluorine atom], or a crystal of a solvate of the compound represented by the formula (I). [Selected figure] Fig. 1
Owner:TEIJIN PHARMA CO LTD

Medium- or macro-cyclic benzyl-substituted heterocycle derivatives and related uses

PendingTW202626665AReceptorPerylene derivatives
The present disclosure relates to compounds of Formula (I’): , and to their prodrugs, pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful for modulating orexin-2 receptor activity and may be used in the treatment of disorders in which orexin-2 receptor activity is implicated, such as narcolepsy, a hypersomnia disorder, a neurodegenerative disorder, a symptom of a rare genetic disorder, a mental health disorder, a metabolic syndrome, osteoporosis, cardiac failure, coma, or facilitating emergence from anaesthesia.
Owner:CENTESSA PHARMACEUTICALS (UK) LIMITED

Pyrazole and imidazole derivatives as dual modulators of orexin and kappa-opioid receptors, compositions, methods for treating neurological and psychiatric patients

The present disclosure relates to substituted pyrazole and imidazole derivatives of compounds that are antagonists and / or modulators of orexin and kappa-opioid receptors that are useful in the treatment or prevention of neurological, psychiatric, cardiovascular and cancer conditions and diseases in which orexin and kappa-opioid receptors are involved or implicated. The disclosure also relates to pharmaceutical compositions comprising these compounds, and the use of these compounds and compositions in the prevention or treatment of diseases associated with orexin and kappa-opioid receptors.
Owner:HAGER BIOSCIENCES LLC

Middle or macrocyclic benzyl substituted heterocyclic derivatives and related uses

PendingCN119110802AOrganic active ingredientsNervous disorderHereditary disordersReceptor
# imgabs0. The disclosure relates to compounds of Formula (I ') and prodrugs, pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods of preparation thereof. The compounds disclosed herein are useful for modulating orexin-2 receptor activity, and can be used to treat disorders in which orexin-2 receptor activity is involved, the pharmaceutical composition can be used for treating or preventing symptoms such as narcolepsy, hyperactivity disorder, neurodegenerative disorder, rare hereditary disorder, psychological health disorder, metabolic syndrome, osteoporosis, heart failure, coma or to promote waking from anesthesia.
Owner:CENTESSA PHARMACEUTICALS (UK) LIMITED

Medium- or large-cyclic benzyl-substituted heterocyclic derivatives and their use as orexin-2 receptor agonists

The present disclosure relates to compounds of formula (I') and their prodrugs, pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful for modulating orexin-2 receptor activity and may be used in the treatment of disorders in which orexin-2 receptor activity is implicated, such as narcolepsy, hypersomnia, neurodegenerative disorders, symptoms of rare genetic diseases, mental health disorders, metabolic syndrome, osteoporosis, heart failure, coma, or promoting emergence from anesthesia. TIFF2023540350000454.tif45128
Owner:センテッサ ファーマシューティカルズ (ユーケー) リミテッド

Methods of treating depression using sitorraxen

A method of treating an orexin-2 mediated condition in a human subject in need thereof is provided. The method comprises administering to the subject a therapeutically effective daily dose of sitorraxen, or a pharmaceutically acceptable salt or hydrate thereof, when the subject is not suffering from liver injury. The method further comprises administering to the subject when the subject is suffering from a moderate liver injury, sitorraxone, or a pharmaceutically acceptable salt or hydrate thereof, in a reduced dose that is lower than the daily dose.
Owner:JANSSEN PHARMA NV

Application of Orexin-A in inhibition of lipid peroxidation

The invention belongs to the technical field of medicines, and particularly relates to application of Orexin-A in inhibiting lipid peroxidation. The invention provides the application of Orexin-A in inhibiting lipid peroxidation for the first time. The application of the OXA in the in-vitro cerebral hemorrhage model shows the potential of the OXA in relieving cell damage, inhibiting ferroptosis and regulating neuroinflammation. The application shows how the OXA realizes the protection effect by influencing a specific signal channel (such as SRC / FAK / ERK1). Multiple roles of the OXA in neuroprotection are disclosed, and a deeper theoretical basis is provided for clinical application of the OXA.
Owner:THE AFFILIATED HOSPITAL OF GUIZHOU MEDICAL UNIV

Oxazepine derivative

To provide a compound having excellent orexin 2 receptor agonist activity.SOLUTION: A compound represented by formula (I) or its pharmaceutically acceptable salt is provided. Specifically, there is shown, for example, (2S, 11aR)-6-isopropoxy-2-((2-oxo-1,2,3,4-tetrahydroquinoline-7-yl)oxy)-2,3,11,11a-tetrahydro-1H,5H-benzo[f]pyrrolo[2,1-c][1,4]oxazepine-5-one.SELECTED DRAWING: None
Owner:TEIJIN PHARMA CO LTD

Pyrazole and imidazole derivatives as dual orexin and kappa-opioid receptors modulators, compositions, and methods for treating neurological and psychiatric disorders

The present disclosure is directed to substituted Pyrazole and Imidazole derivatives of compounds that are antagonists and / or modulators of orexin and kappa-opioid receptors, and which are useful in the treatment or prevention of neurological, psychiatric, cardiovascular and cancer disorders and diseases in which orexin and kappa-opioid receptors are involved or implicated. The disclosure is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which orexin and kappa-opioid receptors are involved.
Owner:HAGER BIOSCIENCES LLC

Heterocyclic compound

To provide a heterocyclic compound with orexin-2 receptor agonistic activity.SOLUTION: A compound represented by formula (I) in the figure or a salt thereof is useful as a preventive or therapeutic agent for narcolepsy.SELECTED DRAWING: None
Owner:TAKEDA PHARMA CO LTD

Oxazepine derivative

Novel compounds are provided with excellent orexin type 2 receptor agonist activity. The compounds are represented by Formula (I) or pharmaceutically acceptable salts thereof.
Owner:TEIJIN PHARMA CO LTD

Aryl sulfone and sulfanone derivatives as orexin receptor modulators

The present invention relates to novel aryl sulfone and sulfanone derivatives of Formula (I), wherein R1, R2, R3, RB1, X1, X2, X3, Ring A, and Ring B are as described in the description, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more compounds of Formula (I), and their use as agonists of the orexin-2 receptor (hereinafter also referred to as OX2R), and particularly as agonists of the human orexin-2 receptor (hereinafter also referred to as hOX2R).
Owner:IDORSIA PHARMACEUTICALS LTD